Skip to Content
Merck
All Photos(2)

Documents

SML3814

Sigma-Aldrich

Firibastat

≥98% (HPLC)

Synonym(s):

QGC-001, (3S)-3-Amino-4-[[(2S)-2-amino-4-sulfobutyl]disulfanyl]butane-1-sulfonic acid, (3S,3′S)-4,4′-Dithiobis(3-aminobutane-1-sulfonic acid, QGC 001, QGC001, RB 150, RB-150, RB150

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C8H20N2O6S4
CAS Number:
648927-86-0
Molecular Weight:
368.51
MDL number:
MFCD20921962
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear (Warmed)

storage temp.

-10 to -25°C

Biochem/physiol Actions

Firibastat (RB150; QGC001) is an orally active, blood-brain barrier-permeant prodrug composed of two molecules of disulfide-linked aminopeptidase A (APA; glutamyl aminopeptidase) active-site inhibitor EC33 (Ki = 300 nM) that are released via the action of brain reductase in the brain. Firibastat exhibits antihypertensive efficacy in vivo (Blood pressure reduction ED50 = 30 mg/kg via p.o. in spontaneously hypertensive rats).

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Aminopeptidase A contributes to biochemical, anatomical and cognitive defects in Alzheimer's disease (AD) mouse model and is increased at early stage in sporadic AD brain
Acta Neuropathologica, 141(6), 823-839 (2021)
Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension
Hypertension, 51(5), 1318-1325 (2008)
Effects of firibastat in combination with enalapril and hydrochlorothiazide on blood pressure and vasopressin release in hypertensive DOCA-salt rats
Biomedicine and Pharmacotherapy, 40, 111682-111682 (2021)
Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats
Journal of Hypertension, 36(3), 641-650 (2018)
Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension
Proceedings of the National Academy of Sciences of the USA, 101(20), 7775-7780 (2004)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service